Esperion Therapeutis.Inc. buy Needham & Company LLC
Summary
This prediction is currently active. With a performance of 1.93%, the BUY prediction by Needham___Company_LL for Esperion Therapeutis.Inc. is trending in the right direction. This prediction currently runs until 28.06.25. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w |
---|---|
Esperion Therapeutis.Inc. | 1.93% |
iShares Core DAX® | 0.238% |
iShares Nasdaq 100 | -0.304% |
iShares Nikkei 225® | 2.271% |
iShares S&P 500 | -0.296% |
Comments by Needham___Company_LL for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by Needham___Company_LL for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
07.05.24
07.05.25
14:08
Esperion Therapeutis.Inc.
10.04.24
10.04.25
14:08
Esperion Therapeutis.Inc.
25.03.24
25.03.25
14:08
Esperion Therapeutis.Inc.
27.02.24
27.02.25
14:08
Esperion Therapeutis.Inc.
07.11.23
07.11.24
14:08
Esperion Therapeutis.Inc.
02.10.23
02.10.24
14:08
Esperion Therapeutis.Inc.
02.08.23
02.08.24
14:08
Esperion Therapeutis.Inc.
29.03.23
29.03.24
30.03.24
Esperion Therapeutis.Inc.
06.03.23
06.03.24
07.03.24